In the latest quarter, 4 analysts provided ratings for Metagenomi (NASDAQ:MGX), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.75, a high estimate of $15.00, and a low estimate of $7.00. Surpassing the previous average price target of $9.00, the current average has increased by 19.44%.
Interpreting Analyst Ratings: A Closer Look
The standing of Metagenomi among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell Kapoor | HC Wainwright & Co. | Raises | Buy | $14.00 | $7.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $7.00 | $7.00 |
| Geulah Livshits | Chardan Capital | Maintains | Buy | $15.00 | $15.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $7.00 | $7.00 |
Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Metagenomi. This information offers a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Metagenomi compared to the broader market. Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Metagenomi's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into Metagenomi's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Metagenomi analyst ratings.
If you are interested in following small-capstock newsand performance you can start by tracking it here.
Discovering Metagenomi: A Closer Look
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
Financial Milestones: Metagenomi's Journey
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Negative Revenue Trend: Examining Metagenomi's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -6.87% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Metagenomi's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -163.04%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.15%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Metagenomi's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.04%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Metagenomi's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
